No profile data available.
InflaRx N.v. (IFRX) is a healthcare company in the antiviral pharmaceuticals industry, based in Jena, Germany, with about 65 full-time employees.
It reported revenue of 165,789 EUR for fiscal year 2024, up 162.8% from fiscal year 2023, and net income of -46.06 million EUR. In Q3 2025 (the quarter ended September 30, 2025) revenue was 23,830 EUR, down 80.8% from a year before. Its market capitalization was $235.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
InflaRx reported 165,789 EUR in revenue for fiscal year 2024, up 162.8% from 63,089 EUR in fiscal year 2023. In Q3 2025 revenue was 23,830 EUR.
$235.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Arcturus Therapeutics Holdings Inc. (ARCT), Agenus Inc. (AGEN), SAB Biotherapeutics, Inc. (SABS), Siga Technologies, Inc. (SIGA).